Abeona Therapeutics names Carsten Thiel new chief executive officer.
M2 PHARMA-April 23, 2018-Abeona Therapeutics names Carsten Thiel new chief executive officer
(C)2018 M2 COMMUNICATIONS
Abeona Therapeutics, a rare genetic disease focused biopharma, has named Carsten Thiel as its new chief executive officer, it was reported on Friday.
Thiel, who was formerly serving as the company's executive vice president and chief commercial officer, brings experience in leading commercial operations to his new position. Following a 25-year career in the biopharmaceutical industry, Thiel has held numerous roles for several biopharma's including Amgen and Roche.
Steven Rouhandeh, executive chairman of Abeona, said, 'As CEO, Carsten Thiel brings a unique combination of extensive experience in research and global rare disease commercialisation to Abeona. In his recent positions, he successfully created value by building cohesive talented teams, driving the commercial success of multiple products globally and fostering entrepreneurial culture; all key aspects that will be critical to our success in these areas in the years ahead.'
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 23, 2018|
|Previous Article:||Helperby Therapeutics reveals phase one study results for AZT and colistin.|
|Next Article:||Zelluna Immunotherapy names Arjan Roozen new chief technology officer.|